Concert Pharmaceuticals announces $8 million milestone from Celgene
![](/46/pdcnewsitem/03/64/69/concert.jpg)
Phase I clinical evaluation of CTP-730 completed.
Concert Pharmaceuticals has achieved an $8 million milestone under its development and license agreement with Celgene Corporation for completion of the Phase I clinical evaluation of CTP-730. CTP-730 is a deuterium-modified analog of apremilast, a selective phosphodiesterase 4 (PDE4) inhibitor. Once-daily dosing of 50 mg of CTP-730 administered for 7 days in the Phase I trial demonstrated similar steady-state exposure to historical data for 30 mg of apremilast administered twice daily.
“We are encouraged by the favorable pharmacokinetic profile of CTP-730 observed in our Phase 1 clinical trials,” stated Roger Tung, President and CEO of Concert Pharmaceuticals. “We believe that selective incorporation of deuterium in apremilast has resulted in a potential next generation anti-inflammatory agent.”
The Phase I program included both single and multiple ascending dose trials. The Phase I clinical trials assessed the safety, tolerability and pharmacokinetics of CTP-730 in 85 healthy subjects. Treatment with CTP-730 was generally well tolerated and no serious adverse events were observed. The most common adverse events were similar to those already identified for apremilast.
The CTP-730 Phase I clinical trials were conducted under a 2013 development and license agreement established by Concert and Celgene to evaluate deuterium-modified compounds for inflammatory diseases and cancer. The collaboration is initially focused on the development of CTP-730, but has the potential to encompass up to three additional programs. Celgene is responsible for all development costs of CTP-730 beyond the Phase I clinical trials conducted by Concert.
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance